ПБиМ 2023 №3 (144)
Subject of the article
ЯРАЛИ КОЛИТ ВА НУТРИТИВ ТЕРАПИЯ (17-20)
Authors
Абдуллаева Умида Курбановна
Institution
Бухоро давлат тиббиёт институти, Ўзбекистон Республикаси, Бухоро ш.
Abstract
Мақолада ярали колит билан оғриган беморлар даволашида нутрициологик қўллаб-қувватлаш мақсадида қўлланиладиган “Модулен IBD” аралашмасининг самараси баҳоланган. Ярали колит билан беморларда қўшимча энтерал озиқлантириш ёрдамида “Модулен IBD” аралашмаси билан овқатланишни қўллаб-қувватлаш курсидан сўнг, овқатланиш ҳолатининг яхшиланиши қайд этилган ва бу тананинг пластик ва энергия захираларининг кўпайишини кўрсатган.
Key words
ярали колит, нутритив статус, энтерал овқатлантириш, “Модулен IBD”.
Literature
1. Клинические рекомендации по язвенному колиту // Министерство Здравоохранения Российской Федерации. 2022 г. 61. стр. 2. Zhang Y, Chen D, Wang F, Li X, Xue X, et al. Comparison of the efficiency of different enemas on patients with distal ulcerative colitis. Cell Prolif. 2019 Mar; 52(2): e12559. Epub 2019 Jan 18. 3. Nguyen NH, Fumery M, Dulai PS, Prokop LJ, et al. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. Lancet Gastroenterol Hepatol. 2018 Nov; 3(11): 742-753. doi: 10.1016/S2468-1253(18) 30231-0. 4. D"Haens G. Systematic review: second-generation vs. conventional corticosteroids for induction of remission in ulcerative colitis. Aliment Pharmacol Ther. 2016; 44: 1018-1029. 5. Lichtenstein GR. Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis. Dig Dis Sci. 2016 Feb; 61(2): 358 – 70. 6. Sherlock ME, MacDonald JK, Griffiths AM, Steinhart AH, Seow CH. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2015 Oct 26; (10): CD007698. 7. Steenholdt C, Bendtzen K, Brynskov J, Ainsworth MA. Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies. Inflamm Bowel Dis. 2016 Aug; 22(8): 1999-2015. 8. Sandborn WJ, C Su, Sands BE, et al. OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017; 376: 1723 – 36. 9. Rizaev J. A. Features of the aggressive forms of periodontitis course //International Journal of Bio-Science and Bio-Technology. – 2019. – Т. 11. – №. 7. – С. 10-16. 10. Shmidt E, Kochhar G, Hartke J, et al. Predictors and Management of Loss of Response to Vedolizumab in Inflammatory. Bowel Disease Inflamm Bowel Dis. 2018; 18 P.